General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc. | prnewswire.com • |
Imagin Medical Secures New $3 Million Convertible Note Financing | globenewswire.com • |
Imagin Medical on Schedule for American Urology Association Demonstration | globenewswire.com • |
IMAGIN MEDICAL REPORTS COMPANY ON SCHEDULE FOR PRODUCT DEMONSTRATION | globenewswire.com • |
IMAGIN MEDICAL REPORTS MANUFACTURING PROGESS | globenewswire.com • |
IMAGIN MEDICAL CLOSES SECOND TRANCHE OF CONVERTIBLE NOTE OFFERING | globenewswire.com • |
Split | Date |
---|---|
1 : 20 | 2020-10-27 |
1 : 3 | 2015-06-17 |
1 : 5 | 2014-06-23 |
Join us on October 29, 2020 at 12:00 pm ET
Click here to register
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company’s initial focus is bladder cancer, the sixth most prevalent cancer in North America and the third most prevalent cancer among men, with a recurrence rate of more than 50%.
Keynote speaker
Jim Hutchens, President and CEO of Imagin Medical
Participants
Ashish M. Kamat, MD - M.D. Anderson Cancer Center, Houston
Alexandre Zlotta, MD - Director of Uro-Oncology, Mt Sinai Hospital, Toronto
Mehrdad Alemozaffar, MD - Kaiser Permanente, Los Angeles
Ron Insana - Senior Analyst, CNBC and Financial Industry Expert
Join us on October 29, 2020 at 12:00 pm ET
Click here to register
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company’s initial focus is bladder cancer, the sixth most prevalent cancer in North America and the third most prevalent cancer among men, with a recurrence rate of more than 50%.
Keynote speaker
Jim Hutchens, President and CEO of Imagin Medical
Participants
Ashish M. Kamat, MD - M.D. Anderson Cancer Center, Houston
Alexandre Zlotta, MD - Director of Uro-Oncology, Mt Sinai Hospital, Toronto
Mehrdad Alemozaffar, MD - Kaiser Permanente, Los Angeles
Ron Insana - Senior Analyst, CNBC and Financial Industry Expert